Diarrhea and constipation are also common
SELECT Trial The SELECT trial, one of the largest cardiovascular outcomes trials in obesity medicine, enrolled over 17,000 participants with established cardiovascular disease and obesity or overweight (without diabetes) and demonstrated a 20% reduction in MACE with semaglutide 2.4 mg
The relationship is always units divided by 100 equals milliliters
Mild, self-limiting burning that resolves within minutes is generally not a cause for concern, but persistent or worsening symptoms warrant medical review to rule out complications
However, direct comparisons require caution because: Trial lengths differed Dosing protocols differed Patient populations differed Long-term orforglipron data is still developing A 5% to 10% reduction in body weight can still produce clinically meaningful improvements in blood pressure, insulin sensitivity, mobility, and metabolic health
Then they spend the next month dealing with severe nausea, vomiting, and the discouraging feeling that semaglutide is not for them